Find a clinical trial


If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

« Previous 12345 Next »
Viewing Page 1 of 65 | Showing Results 1 - 5 of 321

CHECKMATE 817 A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

A study to evaluate the safety of Nivolumab administered in combination with Ipilimumab in patients with advanced cancers. The initial cohort will...

Jason Lukas, M.D., Ph.D.
  • Providence Regional Cancer Partnership - Everett

Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

This randomized phase III trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

GO40241: A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (Impower030)

The purpose of this study is to compare the effects, good or bad, of atezolizumab plus chemotherapy (in this study, chemotherapy will be a...

Timothy Byun, M.D.
  • SJH Southern California

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic
« Previous 12345 Next »
Viewing Page 1 of 65 | Showing Results 1 - 5 of 321